Entero Healthcare Solutions Limited has informed the Exchange regarding Outcome of Board Meeting held on February 12, 2026
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Entero Healthcare Solutions reported its Q3FY26 (quarter ended December 31, 2025) results. On a consolidated basis, revenue from operations rose about 25.6% year-on-year to Rs. 1,706.5 crore, with profit after tax of Rs. 33.9 crore (up 15% YoY). For the nine months, consolidated revenue grew 24.6% to Rs. 4,681.3 crore and PAT grew 32.5% to Rs. 100.7 crore. On a standalone basis, Q3 revenue was Rs. 106.7 crore and PAT was just Rs. 0.8 crore, weighed down by a one-time Rs. 4.5 crore exceptional charge relating to the New Labour Codes (consolidated impact Rs. 8.18 crore). The board also granted 5,000 fresh ESOPs under the existing 2023 plan at an exercise price of Rs. 804 per option, and cancelled the previously announced acquisitions of Khera Medisolutions and AV Medisolutions citing commercial reasons. Statutory auditors MSKA & Associates issued an unmodified review opinion on both standalone and consolidated results.
Consolidated results show healthy double-digit revenue and profit growth, driven by acquisitions and scale, which should be viewed positively by investors. The New Labour Codes charge is a one-time, non-cash item and does not affect ongoing operations. The cancellation of two acquisitions removes a previously announced growth lever but suggests management is being cautious with capital deployment.